510sek
-1,9 %
Date:2024-12-20Time:17:29:31Latest report:Q3-2024List:First NorthTicker:CRNO B
Market Cap:1 438 msekEnterprise Value:1 455 msekNet Sales:- msekEarnings:-81,3 msekEmployees:0ISIN:SE0008241558

Ratios

10-year key figure history for Cereno Scientific turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Cereno Scientific with index and moving average MA50 and MA200.

Stockprice:5,10
MA50:5,37
MA200:5,24
Price/MA200:-2,6 %
RSI (14):39,1
Price/MA50:-4,9 %

Description

Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.

Pharmaceuticals